ARCHIVES

NeoRx Suspends Accrual, Treatment In Phase III trial Using STR For Myeloma.

This article is from The Cancer Letter archive.

Vol. 26 No. 44 | December 1, 2000

Download PDF Visit The Full Archive

Related Articles

Approvals and Applications: European Committee Signs Off On Paxene for KS reatment

March 5, 1999

The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year

April 20, 2012

ACS To Continue Supporting Both Treatment, Prevention Research, Leaders Say

May 1, 1987

Major New Grant Programs Approved In Carcinogenesis, Chemoprevention

May 9, 1980

IL13-PE38 Looks Promising In Early Tests Against Gioma

September 27, 2002

Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

December 5, 2014